ClinicalTrials.gg
Status unknownNCT05363202Updated May 27, 2022

To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma

A Phase 3 interventional study of Fluticasone propionate Inhalation Aerosol 44 mcg and FLOVENT HFA 44 mcg in Bronchial Asthma, sponsored by Glenmark Pharmaceuticals Ltd. India. Status unknown at 11 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-05-27.

Sponsored by Glenmark Pharmaceuticals Ltd. India · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
790
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Asthma with a site in India — 9 open to participants now, 11 under way, 5 of them phase 3. Asthma · India.

Planned enrollment
23rd of 66
790 · median 492
Started
2022
with 3 others
Phase 3
34 of 68
4 open now
Registered
52nd of 68
by date
Lead sponsor
2 of 68
Glenmark Pharmaceuticals Ltd. India

Among the 68 studies in Asthma with a site in India, this one is the 23rd largest by planned enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2022, is one of 34 in phase 3, and was the 52nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

9 of the 68 studies in Asthma with a site in India are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Asthma with a site in India, or all of them as a file.
02

Study summary

This is a randomized, assessor-blind, placebo controlled, multicenter, clinical endpoint bioequivalence study to compare the efficacy and safety of generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark Pharmaceuticals Ltd) to Flovent HFA (fluticasone propionate inhalation aerosol) 44 mcg (GSK group of companies) in treatment of patients with bronchial asthma.

03

Conditions studied

  • Bronchial Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male or female subjects aged between 18 to 65 years of age (both ages inclusive)
  2. Diagnosis of asthma for at least 12 months prior to screening
  3. Pre-bronchodilator of more than or equal to 45 % and less than or equal to 85 %.
  4. Subjects should be stable on their chronic asthma treatment regimen for at least 4 weeks prior to screening
  5. Currently non-smoking;
  6. More than or equal to 15 % reversibility of FEV1 within 30 min following 360 mcg of Albuterol/salbutamol inhalation (pMDI) at screening
  7. Ability to discontinue their asthma controller medication safely
  8. Ability to replace short-acting β agonists (SABAs) ongoing at screening with Albuterol/salbutamol inhaler.
  9. Women of must be willing to consistently use an appropriate method of .
  10. Willingness to give their written to participate in the study.
  11. Is willing to comply with all aspects of the protocol.
  12. Ability to follow training given for study related procedures and assessments in the opinion of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Patients with life-threatening asthma,
  2. Significant respiratory disease other than asthma
  3. Evidence or history of medical, surgical or psychiatric disease or laboratory abnormalities.
  4. Known to any sympathomimetic drug.
  5. Subjects receiving β2-blockers, anti-arrhythmics, anti-depressants, and/or monoamine oxidase inhibitors within 4 weeks prior to the screening.
  6. Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within 4 weeks prior to the screening visit
  7. Subjects who required biologic agents for asthma systemic or oral (for any reason), within the past 6 months prior to screening
  8. Evidence or history of oral candidiasis, active tuberculosis, hypercorticism, adrenal suppression, or eye problems.
  9. Female subjects who are pregnant or breast-feeding or planning to be pregnant.
  10. Currently enrolled in another clinical study or used any product (study drug), study drug, or device within 30 days or 5 elimination half-lives, whichever is longer, preceding .
  11. Consumes excessive amounts of alcohol, abuses drugs, or has any condition that would compromise compliance with this protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
790 participants (estimated)

Study arms

  • Experimental
    Fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark Pharmaceuticals Ltd.)

    Drug: Fluticasone propionate Inhalation Aerosol 44 mcg

  • Active comparator
    FLOVENT HFA

    Drug: FLOVENT HFA 44 mcg

  • Placebo comparator
    Placebo of Fluticasone propionate inhalation aerosol 44 mcg

    Drug: Matching Placebo inhaler

Interventions

  • DrugFluticasone propionate Inhalation Aerosol 44 mcg

    Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation

  • Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation

  • DrugMatching Placebo inhaler

    Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation

06

What researchers measure

Primary outcomes

  1. - Change from baseline in FEV1 measured in the morning prior to dosing of inhaled medications on the last day of 4-week treatment period

    Time frame: From Baseline to last day of 4-week treatment period

07

Study locations

8 of 11 sites recruiting
  • Investigational Site 9
    Ahmedabad, Gujarat 411057, India
    Recruiting
  • Investigational Site 2
    Aurangabad, Maharashtra 431002, India
    Recruiting
  • Investigational Site 6
    Nagpur, Maharashtra 440009, India
    Recruiting
  • Investigational Site 16
    Nashik, Maharashtra 422002, India
    Active, not recruiting
  • Investigational Site 11
    Nashik, Maharashtra 422005, India
    Active, not recruiting
  • Investigational Site 10
    Nashik, Maharashtra 422007, India
    Active, not recruiting
  • Investigational Site 3
    Pune, Maharashtra 411047, India
    Recruiting
  • Investigational Site 1
    Pune, Maharashtra, India
    Recruiting
  • Investigational Site 4
    Jaipur, Rajasthan 302039, India
    Recruiting
  • Investigational Site 13
    Hyderabad, Telangana 500038, India
    Recruiting
  • Investigational Site 5
    Hyderabad, Telangana 500038, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for May 2024, 25 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 25 months is close to that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2022
First posted
May 5, 2022
StartActual
Apr 15, 2022
Primary completionEst.
May 30, 2024
CompletionEst.
Aug 30, 2024
Last update
May 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05363202
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Responsible party
Sponsor
First posted
May 5, 2022
Start date
Apr 15, 2022
Primary completion
May 30, 2024 (estimated)
Completion
Aug 30, 2024 (estimated)
Last update
May 27, 2022

Study contacts

Ameet Daftary, MD
Contact
mahesh.deshpande@glenmarkpharma.com
2016848000
Ameet Daftary
study director · Glenmark Pharmaceuticals Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion